tetano
Editor, Senior Moderator
J Infect Chemother. 2019 Feb 12. pii: S1341-321X(18)30476-8. doi: 10.1016/j.jiac.2018.12.006. [Epub ahead of print]
[h=1]Iron oxide nanoparticles based antiviral activity of H1N1 influenza A virus.[/h] Kumar R[SUP]1[/SUP], Nayak M[SUP]2[/SUP], Sahoo GC[SUP]3[/SUP], Pandey K[SUP]4[/SUP], Sarkar MC[SUP]2[/SUP], Ansari Y[SUP]5[/SUP], Das VNR[SUP]4[/SUP], Topno RK[SUP]4[/SUP], Bhawna[SUP]3[/SUP], Madhukar M[SUP]4[/SUP], Das P[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus is a common human pathogenic agent that has caused serious respiratory illness and death over the past century and in recent year. Treatment options against pandemic influenza strain A/H1N1 are very limited and unsatisfactory. Therefore we have developed iron oxide nanoparticles (IO-NPs) with particle size in the range of 10-15 nm against pandemic influenza strain A/H1N1/Eastern India/66/PR8-H1N1. Cell viability and anti-influenza activity was measured by MTT assay, plaque inhibition and quantifying viral transcripts using quantitative real-time PCR with Iron oxide nanoparticles in a dose- and time-dependent manner. 50% cell viability (TD[SUB]50[/SUB]) was observed at 4.25 pg ? .2 pg of Iron oxide nanoparticles. The percentage of plaque inhibition relative to the infection and the IC[SUB]50[/SUB] (50% virus reduction) of PR8-H1N1strain (0.5 moi) were measured in vitro by the plate forming unit (pfu) in MA104 cells. Finding were observed at 01 pg after 72 h. The Antiviral activity determined by change in viral RNA transcripts within 24 h of virus infection by RT-PCR, 08 fold reductions in virus found when treated with Iron oxide nanoparticles Thus; it opens a new avenue for use of IP-NPs against virus infections.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Antiviral; H1NI; Iron oxide; Peptide; RT-PCR
PMID: 30770182 DOI: 10.1016/j.jiac.2018.12.006
[h=1]Iron oxide nanoparticles based antiviral activity of H1N1 influenza A virus.[/h] Kumar R[SUP]1[/SUP], Nayak M[SUP]2[/SUP], Sahoo GC[SUP]3[/SUP], Pandey K[SUP]4[/SUP], Sarkar MC[SUP]2[/SUP], Ansari Y[SUP]5[/SUP], Das VNR[SUP]4[/SUP], Topno RK[SUP]4[/SUP], Bhawna[SUP]3[/SUP], Madhukar M[SUP]4[/SUP], Das P[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus is a common human pathogenic agent that has caused serious respiratory illness and death over the past century and in recent year. Treatment options against pandemic influenza strain A/H1N1 are very limited and unsatisfactory. Therefore we have developed iron oxide nanoparticles (IO-NPs) with particle size in the range of 10-15 nm against pandemic influenza strain A/H1N1/Eastern India/66/PR8-H1N1. Cell viability and anti-influenza activity was measured by MTT assay, plaque inhibition and quantifying viral transcripts using quantitative real-time PCR with Iron oxide nanoparticles in a dose- and time-dependent manner. 50% cell viability (TD[SUB]50[/SUB]) was observed at 4.25 pg ? .2 pg of Iron oxide nanoparticles. The percentage of plaque inhibition relative to the infection and the IC[SUB]50[/SUB] (50% virus reduction) of PR8-H1N1strain (0.5 moi) were measured in vitro by the plate forming unit (pfu) in MA104 cells. Finding were observed at 01 pg after 72 h. The Antiviral activity determined by change in viral RNA transcripts within 24 h of virus infection by RT-PCR, 08 fold reductions in virus found when treated with Iron oxide nanoparticles Thus; it opens a new avenue for use of IP-NPs against virus infections.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Antiviral; H1NI; Iron oxide; Peptide; RT-PCR
PMID: 30770182 DOI: 10.1016/j.jiac.2018.12.006